NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Eikon Therapeutics EIKN

Eikon Therapeutics listed on Nasdaq on 5 Feb 2026 and is not in the S&P 500. It is worth $258 million. Its price history starts on 6 Feb 2026. Its board has 7 directors, 3 of them independent. 4 other officers are on file. At 30 Jun 2026, Fidelity (FMR) was its largest institutional holder, with 9.2% of the company.

Chair and CEO
Roger M. Perlmutter
Listed
5 Feb 2026 on Nasdaq, IPO filings and terms
Headquarters
Millbrae, CA
Market cap
$258M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Eikon Therapeutics' market cap since February 2026

Weekly, up to 13 Nov 2026

Mar 2026AprMayJunJulAugSepOctNov$320M

Board and leadership

Board and officers

4 people here also hold roles at other S&P 500 companies.

Board from the proxy filed 30 Mar 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (7)
Roger M. PerlmutterChair; Chief Executive Officer and DirectorNot independent 路 since 2021Chair; Chief Executive Officer and Director2021No73
Leon ChenDirectorNot independent 路 since 2019 路 Audit, CompensationPartner, The Column GroupDirector2019NoAudit, Compensation51
Ma. Fatima FranciscoDirectorAlso at HP and Procter & GambleDirector
Kenneth C. FrazierDirectorIndependent 路 since 2022Chairman of Health Assurance initiatives, General CatalystDirector2022Yes71
Robert Luther HuffinesDirectorIndependent 路 since 2023 路 Audit, Compensation (chair)Retired Global Chairman of Investment Banking, J.P. Morgan Chase & Co.Also at Becton Dickinson and InsuletDirector2023YesAudit, Compensation (chair)60
David W. MelineDirectorIndependent 路 Audit (chair), CompensationFormer Chief Financial Officer, Moderna Inc.Also at HPOther boards: Lonza Group AG and ABB Ltd.DirectorYesAudit (chair), Compensation68
Joshua WolfeDirectorNot independent 路 since 2022Co-founder, Lux CapitalDirector2022No48
Officers (4)
Alfred Lloyd Bowie Jr.Chief Financial OfficerLast filed 4 Mar 2026Chief Financial Officer
Roy D. BaynesChief Medical OfficerLast filed 4 Mar 2026Chief Medical Officer
Michael A. KlobucharChief Operating OfficerAlso at RevvityLast filed 4 Mar 2026Chief Operating Officer
Benjamin Bruno ThornerGeneral Counsel and Chief Business OfficerLast filed 4 Mar 2026General Counsel and Chief Business Officer

Owners and trading

Largest institutional holders

Each fund group's share of Eikon Therapeutics. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 28.6% of Eikon Therapeutics.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $12.0 million in 2 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
4 Feb 2026BuyJosh WolfeDirectorDirectorBuy555,552$10.0M
4 Feb 2026BuyKenneth C. FrazierDirectorDirectorBuy111,111$2.0M

Workforce and hiring

WARN layoff notices

Notices filed under Eikon Therapeutics' own name or a subsidiary's listed in its 10-K.

Notices from 19 Nov 2023 to 19 Nov 2026

Eikon Therapeutics filed 1 notice covering 55 workers since November 2023.

NoticePlaceWorkersEffective
21 May 2025Millbrae, CA5521 Jul 2025

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

2 departures and 1 appointment of directors and officers and WARN layoff notices on 1 day in the last two years.

Left the company or board 2Appointed 1WARN layoff notices 1Large insider sales 0Jan 2025AprJulOctJan 2026AprJulOct

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.